Karuna Therapeutics, Inc. Common Stock
KRTX
KRTX was delisted on the 15th of March, 2024.
157 hedge funds and large institutions have $3.02B invested in Karuna Therapeutics, Inc. Common Stock in 2021 Q1 according to their latest regulatory filings, with 32 funds opening new positions, 49 increasing their positions, 55 reducing their positions, and 17 closing their positions.
88% more first-time investments, than exits
New positions opened: 32 | Existing positions closed: 17
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
38% more capital invested
Capital invested by funds: $2.19B → $3.02B (+$835M)
10% more funds holding
Funds holding: 143 → 157 (+14)
11% less repeat investments, than reductions
Existing positions increased: 49 | Existing positions reduced: 55
73% less call options, than puts
Call options by funds: $4.46M | Put options by funds: $16.4M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$78.2M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$59.3M |
| 3 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$52.6M |
| 4 |
CCM
CAAS Capital Management
New York
|
+$42.9M |
| 5 |
MVP
Miller Value Partners
Sarasota,
Florida
|
+$33M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PBPIA
Pivotal bioVenture Partners Investment Advisor
San Francisco,
California
|
-$19.8M |
| 2 |
Norges Bank
Oslo,
Norway
|
-$11.9M |
| 3 |
MWNA
Marshall Wace North America
New York
|
-$9.31M |
| 4 |
State Street
Boston,
Massachusetts
|
-$7.65M |
| 5 |
Millennium Management
New York
|
-$6.08M |
KRTX Hedge Fund Activity: Q1 2021 in Review
157 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Karuna Therapeutics, Inc. Common Stock (KRTX) for Q1 2021, worth a combined $3.02B — up 38% from $2.19B a quarter earlier.
Buyers outnumbered sellers: 32 funds opened new KRTX positions and 17 closed out — a net gain of 15 holders — while 49 added to existing stakes and 55 trimmed.
The largest buyer was Vanguard Group, adding an estimated $78.2M. The largest seller was Pivotal bioVenture Partners Investment Advisor, cutting an estimated $19.8M.
- 157 institutional investors held Karuna Therapeutics, Inc. Common Stock (KRTX) as of Q1 2021, up from 143 in Q4 2020.
- Funds reported $3.02B of Karuna Therapeutics, Inc. Common Stock stock for Q1 2021, up 38% quarter-over-quarter.
- 32 funds opened new Karuna Therapeutics, Inc. Common Stock positions in Q1 2021 and 17 closed out, a net change of +15 holders.
- The largest Karuna Therapeutics, Inc. Common Stock buyer in Q1 2021 was Vanguard Group, an estimated $78.2M added.
- The largest Karuna Therapeutics, Inc. Common Stock seller in Q1 2021 was Pivotal bioVenture Partners Investment Advisor, an estimated $19.8M sold.
Based on aggregated 13F filings for Q1 2021.